Intellia Therapeutics (NTLA) Return on Capital Employed Growth (3y) (2019 - 2026)
Intellia Therapeutics (NTLA) Return on Capital Employed Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4,893.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2,416.00 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -3,782.00 |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - | -2,692.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,692.00 |
| Dec 31, 2025 | -1,758.00 |
| Sep 30, 2025 | -1,416.00 |
| Jun 30, 2025 | -2,221.00 |
| Mar 31, 2025 | -2,286.00 |
| Dec 31, 2024 | -2,734.00 |
| Sep 30, 2024 | -2,457.00 |
| Jun 30, 2024 | -1,681.00 |
| Mar 31, 2024 | -2,017.00 |
| Dec 31, 2023 | -1,739.00 |
| Sep 30, 2023 | -1,116.00 |
| Jun 30, 2023 | -93.00 |
| Mar 31, 2023 | 879.00 |
| Dec 31, 2022 | -407.00 |
| Sep 30, 2022 | -1,315.00 |
| Jun 30, 2022 | -723.00 |
| Mar 31, 2022 | -249.00 |
| Dec 31, 2021 | 841.00 |
| Sep 30, 2021 | 577.00 |
| Jun 30, 2021 | -327.00 |